A new model for the evaluation, introduction and reimbursement of new therapies against rare diagnoses

In this IHE report the author has identified a number of conditions which lead to the fact that today’s methods of valuing medicines hardly lead us to a satisfactory understanding of the value of orphan medicines. The insurance value is not included. The value of hope is not included, Process-related benefits are not included. The international discussion of how to make the valuation methods more in line with economic theory and including individual preferences are reported and ends up in suggestions for improvements.

This report is an English translation of IHE Rapport 2023:5

For more information, please contact Ulf Persson

IHE Report 2023:5b, IHE: Lund, Sweden